77 related articles for article (PubMed ID: 26038340)
21. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
[TBL] [Abstract][Full Text] [Related]
22. CD44 as a molecular marker to screen cancer stem cells in hypopharyngeal cancer.
Shen C; Xiang M; Nie C; Hu H; Ma Y; Wu H
Acta Otolaryngol; 2013 Nov; 133(11):1219-26. PubMed ID: 23837451
[TBL] [Abstract][Full Text] [Related]
23. Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-κB/microRNA 448 circuit.
Mak KK; Wu AT; Lee WH; Chang TC; Chiou JF; Wang LS; Wu CH; Huang CY; Shieh YS; Chao TY; Ho CT; Yen GC; Yeh CT
Mol Nutr Food Res; 2013 Jul; 57(7):1123-34. PubMed ID: 23504987
[TBL] [Abstract][Full Text] [Related]
24. Screening of peptides bound to breast cancer stem cell specific surface marker CD44 by phage display.
Park HY; Lee KJ; Lee SJ; Yoon MY
Mol Biotechnol; 2012 Jul; 51(3):212-20. PubMed ID: 21979823
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of Ezrin and CD44 co‑expression in breast cancer.
Ma L; Jiang T
Oncol Rep; 2013 Oct; 30(4):1899-905. PubMed ID: 23900701
[TBL] [Abstract][Full Text] [Related]
26. Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer.
Cho Y; Lee HW; Kang HG; Kim HY; Kim SJ; Chun KH
Oncotarget; 2015 Apr; 6(11):8709-21. PubMed ID: 25909162
[TBL] [Abstract][Full Text] [Related]
27. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
[TBL] [Abstract][Full Text] [Related]
28. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
Ling LJ; Wang S; Liu XA; Shen EC; Ding Q; Lu C; Xu J; Cao QH; Zhu HQ; Wang F
Chin Med J (Engl); 2008 Oct; 121(20):1980-6. PubMed ID: 19080260
[TBL] [Abstract][Full Text] [Related]
29. CD44-specific supramolecular hydrogels for fluorescence molecular imaging of stem-like gastric cancer cells.
Park J; Ku M; Kim E; Park Y; Hong Y; Haam S; Cheong JH; Park ES; Suh JS; Huh YM; Yang J
Integr Biol (Camb); 2013 Apr; 5(4):669-72. PubMed ID: 23403616
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
31. ALDH/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas.
Adams A; Warner K; Pearson AT; Zhang Z; Kim HS; Mochizuki D; Basura G; Helman J; Mantesso A; Castilho RM; Wicha MS; Nör JE
Oncotarget; 2015 Sep; 6(29):26633-50. PubMed ID: 26449187
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer stem cells expressing different stem cell markers exhibit distinct biological characteristics.
Shao J; Fan W; Ma B; Wu Y
Mol Med Rep; 2016 Dec; 14(6):4991-4998. PubMed ID: 27840965
[TBL] [Abstract][Full Text] [Related]
33. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
Gudadze M; Kankava Q; Mariamidze A; Burkadze G
Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers for breast cancer stem cells: the challenges ahead.
Gökmen-Polar Y; Nakshatri H; Badve S
Biomark Med; 2011 Oct; 5(5):661-71. PubMed ID: 22003917
[TBL] [Abstract][Full Text] [Related]
35. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B
Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168
[TBL] [Abstract][Full Text] [Related]
36. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G
J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409
[TBL] [Abstract][Full Text] [Related]
37. STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer.
Wei W; Tweardy DJ; Zhang M; Zhang X; Landua J; Petrovic I; Bu W; Roarty K; Hilsenbeck SG; Rosen JM; Lewis MT
Stem Cells; 2014 Oct; 32(10):2571-82. PubMed ID: 24891218
[TBL] [Abstract][Full Text] [Related]
38. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production.
Hiraga T; Ito S; Nakamura H
Cancer Res; 2013 Jul; 73(13):4112-22. PubMed ID: 23633482
[TBL] [Abstract][Full Text] [Related]
39. Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis.
Huang X; Sheng Y; Guan M
Surg Oncol; 2012 Jun; 21(2):103-7. PubMed ID: 21764578
[TBL] [Abstract][Full Text] [Related]
40. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells.
Xu L; Zhang L; Hu C; Liang S; Fei X; Yan N; Zhang Y; Zhang F
Int J Oncol; 2016 Mar; 48(3):1175-86. PubMed ID: 26781188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
